Event JSON
{
"id": "92b49746a95f493328be14641eca185997125456c469e97f22672da3c4419f2b",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1731665130,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/forget-eli-lilly-buy-magnificent-090500775.html"
],
[
"subject",
"Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?"
],
[
"published_at",
"1731661500"
],
[
"image",
"https://media.zenfs.com/en/motleyfool.com/45ec9a26e9918ba176af4d983140d88a"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/motleyfool.com/45ec9a26e9918ba176af4d983140d88a"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"Viking Therapeutics is a biotech company that is developing a weight loss drug, VK2735, which has shown promising results in clinical trials. The company is planning to launch phase 3 trials and has a potential oral formulation that could make administration easier for patients. While Eli Lilly and Novo Nordisk are the current leaders in the weight loss market, there is room for new players to succeed, and Viking Therapeutics may be a good option for investors looking for a dynamic growth stock."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy\nhttps://media.zenfs.com/en/motleyfool.com/45ec9a26e9918ba176af4d983140d88a\n\nhttps://finance.yahoo.com/news/forget-eli-lilly-buy-magnificent-090500775.html",
"sig": "06962b1ad5214e4b641420a99efa83fcef49254970f7db1bbf62114aeb545ae48866a0e2070cdef297434f1760870d07a537e34f95ba7de8b6f18f1c4fa9957e"
}